The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis

Lin, RF; Zhang, Z; Cao, ST; Yang, W; Zuo, YL; Yang, XY; Zhang, JC; Xu, J; Li, J; Wang, XJ

Wang, XJ (corresponding author), HEC Pharma Co Ltd, Dept Cardiovasc Dis, Shangsha Fifth Ind Pk, Dongguan 523871, Guangdong, Peoples R China.

RSC MEDICINAL CHEMISTRY, 2021; 12 (7): 1222

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfeni......

Full Text Link